Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate has disclosed a change in director Kim Wenn’s beneficial interest in the company’s shares, relating to a purchase made on 15 December 2025 that was notified to the company later than required due to personal circumstances. The company emphasised that its continuous disclosure and securities trading policies remain robust, outlined the internal process used to prepare and lodge director interest notices within the ASX’s five‑day deadline, and noted that both Cogstate and Ms Wenn have implemented additional safeguards and personal processes to prevent similar administrative oversights and reinforce compliance with ASX listing obligations.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is an ASX-listed neuroscience technology company that develops and provides digital brain health assessment tools to support the development of new medicines and deliver earlier clinical insights in healthcare. Its computerised cognitive testing platforms and electronic clinical outcome assessment solutions are used by biopharmaceutical companies, academic institutions, physicians and patients worldwide, with a growing focus on brief, self-administered and scientifically validated measures of cognition for primary care and consumer markets.
Average Trading Volume: 317,769
Technical Sentiment Signal: Buy
Current Market Cap: A$425.6M
See more insights into CGS stock on TipRanks’ Stock Analysis page.